Sunday - July 6, 2025
Johnson & Johnson seeks U.S. FDA approval of STELARA(r) (ustekinumab) for the treatment of pediatric Crohn's disease
June 17, 2025
NEW BRUNSWICK, New Jersey, June 17 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

Johnson & Johnson seeks U.S. FDA approval of STELARA(r) (ustekinumab) for the treatment of pediatric Crohn's disease

*

HORSHAM, Pa. (June 17, 2025) - Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products